Urinary Exosomal Thyroglobulin in Thyroid Cancer Patients With Post-ablative Therapy: A New Biomarker in Thyroid Cancer

Tse-Ying Huang, Chih-Yuan Wang, Kuen-Yuan Chen, Li-Ting Huang, Tse-Ying Huang, Chih-Yuan Wang, Kuen-Yuan Chen, Li-Ting Huang

Abstract

Background: Most patients with thyroid cancer typically receive thyroidectomy with ablative radioactive iodine therapy. Such patients were followed with thyroid ultrasonography and serial serum thyroglobulin evaluation. Exosomes are nanovesicles secreted into extracellular environments, including plasma, saliva, urine, and other body fluids of patients with cancer. We try to find the early prognostic and exosomal biological markers of urine. Methods: We analyzed urinary exosomal proteins, including thyroglobulin and galectin-3, to identify early prognostic biological markers in urine for patients receiving operation and radioactive iodine ablative therapy. We enrolled sixteen newly diagnosed patients with papillary thyroid carcinoma and follicular thyroid carcinoma. We collect all patient's urine samples before operation, immediately after operation, post-operatively at three and six months (4 collections per patient). The levels of pre-operative and post-ablative of U-Ex Tg and galectin-3 in patients with thyroid cancer were measured. Results: Trends in urinary thyroglobulin concentrations in patients with post-ablative thyroid cancer were detected in the first sixteen patients. Importantly, serum thyroglobulin was not detected in five patients after operation and radioactive I-131 ablation, while U-Ex Tg still showed an increasing trend, which implicating the probable recurrence of thyroid cancer. This is the first study to evaluate whether U-Ex Tg is a future biological marker as a substitute for serum thyroglobulin. Conclusion: Our study have developed a brand-new evaluation for tracking thyroid cancer. The most useful scenario in using a test that is potentially more sensitive than existing serological testing is to eliminate the suspicion of recurrence and remove subjects from long term follow up. Trial Registration: ClinicalTrials.gov: NCT02862470; 5, August 2016. https://ichgcp.net/clinical-trials-registry/NCT02862470?term=NCT02862470&rank=1. ClinicalTrials.gov: NCT03488134; 3, August 2018. https://ichgcp.net/clinical-trials-registry/NCT03488134?term=NCT03488134&draw=2&rank=1.

Keywords: exosome; galectin-3; thyroglobulin; thyroid cancer; urine.

Copyright © 2020 Huang, Wang, Chen and Huang.

Figures

Figure 1
Figure 1
Urinary exosomal thyroglobulin revealed statistically significant in larger tumor (T3) or lymph nodes metastasis in pathological report.
Figure 2
Figure 2
Urinary exosomal thyroglobulin showed an increasing trend in patients of post thyroidectomy and/or I-131 ablation in comparison with serum thyroglobulin.

References

    1. Wang TS, Sosa JA. Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol. (2018) 14:670–83. 10.1038/s41574-018-0080-7
    1. Conzo G, Avenia N, Bellastella G, Candela G, de Bellis A, Esposito K, et al. . The role of surgery in the current management of differentiated thyroid cancer. Endocrine. (2014) 47:380–8. 10.1007/s12020-014-0251-9
    1. Docimo G, Tolone S, Ruggiero R, Gubitosi A, Pasquali D, De Bellis A, et al. . Total thyroidectomy without prophylactic central neck dissection combined with routine oral calcium and vitamin D supplements: is it a good option to achieve a low recurrence rate avoiding hypocalcemia? A retrospective study. Minerva Chir. (2013) 68:321–8.
    1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. . American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer. Thyroid. (2016) 26:1–133. 10.1089/thy.2015.0020
    1. Haugen BR. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: What is new and what has changed? Cancer. (2017) 123:372–81. 10.1002/cncr.30360
    1. Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M. Thyroglobulin measurement before rhTSHaided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf). (2008) 69:659–63. 10.1111/j.1365-2265.2008.03244.x
    1. Rosario PW, Xavier AC, Calsolari MR. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid. (2011) 21:49–53. 10.1089/thy.2010.0145
    1. Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, et al. . Diagnosis of Endocrine disease: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol. (2014) 171:R33–46. 10.1530/EJE-14-0148
    1. Soung YH, Nguyen T, Cao H, Lee J, Chung J. Emerging roles of exosomes in cancer invasion and metastasis. BMB Rep. (2016) 49:18–25. 10.5483/BMBRep.2016.49.1.239
    1. Properzi F, Logozzi M, Fais S. Exosomes: the future of biomarkers in medicine. Biomark Med. (2013) 7:769–78. 10.2217/bmm.13.63
    1. Simpson RJ, Jensen SS, Lim WE. Proteomic profiling of exosomes: current perspectives. Proteomics. (2008) 8:4083–99. 10.1002/pmic.200800109
    1. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics. (2006) 5:1760–71. 10.1074/mcp.R600004-MCP200
    1. Huebner AR, Somparn P, Benjachat T, Leelahavanichkul A, Avihingsanon Y, Fenton RA, et al. . Exosomes in urinary biomarker discovery. Adv Exp Med Biol. (2015) 845:43–58. 10.1007/978-94-017-9523-4_5
    1. Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer. (2005) 92:1188–92. 10.1038/sj.bjc.6602493
    1. Lin TW, Chang HT, Chen CH, Chen CH, Lin SW, Hsu TL, et al. . Galectin-3 binding protein and galectin-1 interaction in breast cancer cell aggregation and metastasis. J Am Chem Soc. (2015) 137:9685–93. 10.1021/jacs.5b04744
    1. Tang WW, Huang CW, Tang CY, Xu J, Wang H. Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis. Onco Targets Ther. (2016) 9:455–60. 10.2147/OTT.S94514
    1. Moon PG, You S, Lee JE, Hwang D, Baek MC. Urinary exosomes and proteomics. Mass Spectrom Rev. (2011) 30:1185–1202. 10.1002/mas.20319
    1. Street JM, Koritzinsky EH, Glispie DM, Star RA, Yuen PS. Urine exosomes: an emerging trove of biomarkers. Adv Clin Chem. (2017) 78:103–22. 10.1016/bs.acc.2016.07.003
    1. Desdín-Micó G, Mittelbrunn M. Role of exosomes in the protection of cellular homeostasis. Cell Adh Migr. (2017) 11:127–34. 10.1080/19336918.2016.1251000

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren